Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMLI vs TBI Conditioning for Haplo-HSCT in Adult ALL
NCT06564545Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Mar 2025
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Relapse-free survival at 2 years, acute Graft Versus Host Disease at 100 days and 1 more. Started Mar 2025; status: recruiting.
Beyond the preview
Go deeper on NCT06564545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06564545.